ArticleCureus2026
Reversible Cerebral Vasoconstriction Syndrome Associated With Vortioxetine: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reversible cerebrovascular syndrome (RCVS) is a condition that is clinically characterized by sudden and severe headaches, and its imaging hallmark consists of multifocal phenomena of reversible cerebral vasoconstriction. Multiple triggers are associated with its occurrence, including many types of medication. A 55-year-old woman with a history of recurrent depressive disorder treated with vortioxetine presented with a sudden-onset thunderclap headache triggered by physical exertion. Neurological examination was unremarkable. CT angiography demonstrated multifocal segmental irregularities involving the bilateral middle cerebral artery branches and pericallosal vessels, consistent with RCVS. No alternative precipitating factors were identified. Vortioxetine was discontinued and replaced with trazodone following Liaison Psychiatry consultation. The patient experienced complete clinical recovery with supportive treatment and was discharged without neurological deficits. This case highlights vortioxetine as a possible precipitating factor for RCVS and supports the growing evidence implicating serotonergic antidepressants in the syndrome. Clinicians should consider RCVS in patients presenting with a thunderclap headache, even after a single episode and in the absence of focal neurological deficits. Prompt recognition, vascular imaging, and withdrawal of the suspected precipitating agent are essential to minimize the risk of neurological complications. Further case reports and pharmacovigilance studies are needed to better define the relationship between vortioxetine and RCVS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.